Skip to search formSkip to main contentSkip to account menu

valspodar

Known as: valspodar [Chemical/Ingredient], 3'-keto-Bmt(1)-Val(2)-cyclosporin A, SZD PSC 833 
An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity… 
National Institutes of Health

Related topics

Related topics

12 relations
ABCB1 protein, humanMultidrug Resistance Inhibition processNCIt Antineoplastic Agent TerminologyPSC 833/vinblastine

Broader (1)

Cyclosporins

Narrower (1)

SDZ PSC 833

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Reversal of drug resistance in ovarian cancer: where do we go from here?
Disease management in patients with ovarian cancer exemplifies the fundamental problem underlying much of today’s cancer… 
2006
2006
DEMONSTRATION OF DOCOSAHEXAENOIC ACID AS A BIOAVAILABILITY ENHANCER FOR CYP3A SUBSTRATES: IN VITRO AND IN VIVO EVIDENCE USING CYCLOSPORIN IN RATS
To investigate the pharmacokinetic interaction between cyclosporin A (CsA) and docosahexaenoic acid (DHA) in vivo, 5 mg/kg CsA… 
2005
2005
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
PURPOSE The aim of this study was to determine (i) the maximum tolerated dose (MTD) of liposomal doxorubicin (L-DOX) and… 
2003
2003
Effect of valspodar on the pharmacokinetics of unbound paclitaxel
The aim of this multicenter study was to determine whether valspodar (Amdray™; code designation, SDZ PSC 833), a potent P… 
2001
2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
PSC 833 (Valspodar) can reverse multidrug resistance (MDR) in patients with hematologic malignancies, but alters the… 
2001
2001
A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents
Background: The cyclosporins have been thought as being mainly immunosuppressive agents which interfere with the function of the… 
2000
2000
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
PURPOSE To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of… 
2000
2000
Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells
Paclitaxel (Taxol®) kills tumor cells by inducing both cellular necrosis and apoptosis. A major impediment to paclitaxel… 
1999
1999
Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit…
Coadministration of anticancer drugs and multidrug resistance modulators directed against P-glycoprotein over-expressed in tumors… 
Review
1999
Review
1999
Valspodar: current status and perspectives.
Valspodar (Amdray, SDZ PSC 833) is derived from cyclosporin, but lacks the immunosuppressive and most of the collateral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)